SEC Form 4 · accession 0001615774-18-004659
ATOSSA GENETICS INC · ATOS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shu-Chih Chen
Director
Period of report
May 30, 2018
Accepted (ET)
May 31, 2018 · 3:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001488039
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B Convertible Preferred StockF4,F5,F1,F2,F3 | $3.52 | May 30, 2018 | P | 8 | A | May 30, 2018 | — | Common Stock | 2,273 | 8 | I |
| WarrantsF4,F5 | $4.05 | May 30, 2018 | P | 2,272 | A | May 30, 2018 | May 30, 2022 | Common Stock | 2,272 | 2,272 | I |
Explanation of responses
- F1Each share of Series B Convertible Preferred Stock is convertible into the number of shares of Common Stock equal to the stated value of $1,000 divided by $3.52.
- F2Shares of Series B Convertible Preferred Stock do not expire.
- F3No fractional shares will be issued upon conversion. At its election, the Company will either issue a cash adjustment or round up to the next whole share. The number reflected here assumes rounding up to the next whole share.
- F4Shares of Series B Convertible Preferred Stock and Warrants were issued as part of a unit, with each unit consisting of one share of Series B Convertible Preferred Stock and 284 Warrants.
- F5Securities are owned by Ensisheim Partners, LLC ("Ensisheim"). Shu-Chih Chen, Ph.D. and Steven C. Quay, M.D., Ph.D., share voting and investment power over the securities held by Ensisheim. Ensisheim is solely owned and controlled by Drs. Chen and Quay, and, as a result, Drs. Chen and Quay are deemed to be beneficial owners of the shares held by this entity.